pricing market access

PMA Insights: Week 1


We summarise key insights from the pharmaceutical, pricing and market access sector:


  • Kidney Research UK deems NICE process “not appropriate for a rapidly evolving virus
  • Sharp criticism is received for the increased VPAS clawback rate of 26.5% in 2023
  • Health benefits paid by supplementary bodies jumped by 11.6% last year

Our Latest Articles:

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.